Advertisement
Canada markets closed

  • S&P/TSX

    22,781.43
    -206.85 (-0.90%)
     

  • S&P 500

    5,408.42
    -94.99 (-1.73%)
     

  • DOW

    40,345.41
    -410.34 (-1.01%)
     

  • CAD/USD

    0.7370
    -0.0037 (-0.50%)
     

  • CRUDE OIL

    68.16
    -0.99 (-1.43%)
     

  • Bitcoin CAD

    74,056.16
    +420.48 (+0.57%)
     

  • XRP CAD

    0.72
    +0.00 (+0.50%)
     

  • GOLD FUTURES

    2,526.80
    -16.30 (-0.64%)
     

  • RUSSELL 2000

    2,091.41
    -40.65 (-1.91%)
     

  • 10-Yr Bond

    3.7100
    -0.0210 (-0.56%)
     

  • NASDAQ

    16,690.83
    -436.83 (-2.55%)
     

  • VOLATILITY

    22.38
    +2.48 (+12.46%)
     

  • FTSE

    8,181.47
    -60.24 (-0.73%)
     

  • NIKKEI 225

    36,391.47
    -265.62 (-0.72%)
     

  • CAD/EUR

    0.6644
    -0.0019 (-0.29%)
     

Compared to Estimates, Pacific Biosciences (PACB) Q2 Earnings: A Look at Key Metrics

Zacks Equity Research
·2 min read

For the quarter ended June 2024, Pacific Biosciences of California (PACB) reported revenue of $36.01 million, down 24.3% over the same period last year. EPS came in at -$0.20, compared to -$0.26 in the year-ago quarter.

The reported revenue represents a surprise of -11.12% over the Zacks Consensus Estimate of $40.52 million. With the consensus EPS estimate being -$0.24, the EPS surprise was +16.67%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Pacific Biosciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- Product- Instrument

    : $14.70 million compared to the $18.58 million average estimate based on three analysts.

  • Revenue- Product

    : $31.75 million versus $36.51 million estimated by three analysts on average.

  • Revenue- Service and other

    : $4.27 million versus the three-analyst average estimate of $3.91 million. The reported number represents a year-over-year change of +8.9%.

  • Revenue- Product- Consumable

    : $17 million versus $17.92 million estimated by three analysts on average.

View all Key Company Metrics for Pacific Biosciences here>>>

Shares of Pacific Biosciences have returned +22.1% over the past month versus the Zacks S&P 500 composite's -5.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research